儿童炎性肠病抗肿瘤坏死因子治疗疗效预测研究进展  

Research advance in predicting the efficacy of anti-TNF therapy for pediatric inflammatory bowel disease

作　　者：韩亚楠[1] 方莹[1] HAN Ya-nan;FANG Ying(Department of Gastroenterology,Xi'an Children's hospital,Xi'an 710003,China)

机构地区：[1]西安市儿童医院消化科,陕西西安710003

出　　处：《中国实用儿科杂志》2023年第4期262-266,共5页Chinese Journal of Practical Pediatrics

基　　金：陕西省自然科学基础研究计划青年项目[项目编号:2020JQ-928]。

摘　　要：抗肿瘤坏死因子(TNF)单克隆抗体(抗TNF单抗)是目前惟一批准用于儿童炎性肠病(IBD)的生物制剂。然而在临床诊治过程中,因该治疗存在较高比例的原发性或继发性失应答,使部分炎性肠病患儿的临床获益受限。因此,在治疗前预测生物制剂疗效,从而寻找适宜人群进行生物制剂治疗在临床决策中显得尤为重要。文章就近年报道的抗TNF单抗治疗IBD的疗效预测研究进行综述。Anti-tumor necrosis factor(TNF)monoclonal anti-body is currently the only approved biological agent for pediatric inflammatory bowel disease.However,due to the high proportion of primary or secondary loss of response to this treatment,the clinical benefit to some children with inflammatory bowel disease is limited.Therefore,it is particularly important for clinicians to predict the efficacy of biological agents before treatment and to find the suitable population for biological agents treatment.This article reviews the recent studies on the prediction of the efficacy of anti-TNF monoclonal antibodies in the treatment of pediatric IBD.

关 键 词：儿童 炎性肠病 抗肿瘤坏死因子-Α 疗效 预测 

分 类 号：R72[医药卫生—儿科]